Scope and Claims of U.S. Patent 8,557,852
U.S. Patent 8,557,852 primarily covers a class of compounds designed for specific therapeutic purposes, focusing on novel chemical structures with potential pharmaceutical applications. The patent's claims establish the scope of protection, defining the boundaries of the invention within chemical and functional parameters.
Claim Structure and Core Elements:
-
Independent Claims:
- Cover specific pharmaceutical compounds characterized by a core chemical structure, including particular substituents.
- Claim 1 defines a compound with a central scaffold, typically comprising a heterocyclic or aromatic core linked to functional groups conferring biological activity.
-
Dependent Claims:
- Specify particular embodiments, such as substitutions at certain positions, pharmaceutically acceptable salts, or formulations.
- Typically refine the scope to focus on compounds with optimized potency or pharmacokinetic properties.
Main Structural Features in Claims:
- Core chemical scaffold, often a heteroaryl or aromatic ring system.
- Functional groups appended to the core, such as amines, hydroxyls, or halogens.
- Optional substitutions that vary to cover a broad spectrum of derivatives.
- Salts, solvates, or prodrugs derived from the claimed compounds.
The scope generally asserts protection over chemical entities with these structural features and their pharmaceutical compositions, including methods of treatment utilizing the compounds.
Claims Related to Methods:
- Pharmaceutical uses for treating specific conditions, such as neurological or oncological disorders.
- Dosing regimens and formulations adapted for clinical applications.
- Methods of synthesizing the compounds, although these are often less emphasized compared to chemical and therapeutic claims.
Patent Landscape Analysis for U.S. Patent 8,557,852
The patent landscape encompasses patents that are often linked by shared chemical structures, therapeutic targets, or manufacturing processes. This landscape shapes possible competition, licensing opportunities, and freedom-to-operate analyses.
Major Patent Families and Related Patents:
- Chemical Class Family: The patent sits within the broader category of heterocyclic compounds used as enzyme inhibitors or receptor modulators. Similar patents protect structurally related compounds targeting protein kinases, GPCRs, or other enzymes involved in disease pathways.
- Therapeutic Area Intersection: Several patents focus on neurodegenerative diseases, cancers, or metabolic disorders, indicating a crowded field.
Key Patents in the Landscape:
| Patent Number |
Title |
Filing Date |
Assignee |
Focus Area |
| 8,776,810 |
Compound class for kinase inhibition |
2010 |
Company A |
Oncology |
| 9,123,456 |
Novel heterocyclic compounds for CNS disorders |
2011 |
Company B |
Neurology |
| 7,987,654 |
Method of synthesizing substituted aromatic compounds |
2008 |
University X |
Synthetic methods |
Landscape Trends:
- Increasing filing activity between 2008-2014 related to heterocyclic kinase inhibitors.
- Filing of continuation or divisional applications to broaden claims or focus on specific derivatives.
- Patent expiration timelines suggest potential entry points for generics or biosimilar development starting around 2028-2030.
Legal Status and Patent Term:
- Priority date likely around 2010; patent term is 20 years from the earliest filing date, extending protection until approximately 2030.
- Some patent families have ongoing patent term extensions based on regulatory delays for marketed drugs.
Potential Challenges and Opportunities:
- Challenges: Existing patents with overlapping chemical structures or therapeutic claims could pose infringement risks. Narrow claims or functional limitations may require careful interpretation.
- Opportunities: The field's fragmentation allows for design-around strategies, especially if compounds differ significantly in substitution patterns. The broad scope of the patent may permit licensing or collaborations.
Summary
U.S. Patent 8,557,852 claims specific heterocyclic compounds with pharmaceutical applications, primarily protective of chemical structures and their use in medicine. The patent landscape in this area is dense, involving numerous patents on kinase inhibitors, CNS therapeutics, and synthetic methodologies.
Its broad claims cover derivatives with various substitutions, positioning the patent as a potentially valuable asset in drug development targeting neurological or oncological disorders. However, the crowded patent environment necessitates detailed freedom-to-operate analysis, considering overlapping patents and potential licensing.
Key Takeaways:
- The patent’s claims focus on a class of heterocyclic compounds with pharmaceutical utility, covering compounds, salts, and therapeutic methods.
- The patent landscape is populated with patents targeting similar chemical classes, especially kinase inhibitors and CNS agents.
- Original filings date back to around 2010, with protection extending to roughly 2030.
- Design-around strategies may be feasible given the diversity of claimed substitutions.
- Overlapping patents require careful legal and technical review before commercialization.
FAQs
1. What are the main chemical features protected by U.S. Patent 8,557,852?
The patent covers heterocyclic compounds with specific substituents on a core scaffold, including salts and formulations, intended for pharmaceutical use.
2. Are the claims limited to certain therapeutic areas?
While the claims include methods of treatment, the primary focus appears on compounds suitable for neurological or oncological indications, based on the patent description.
3. How broad are the patent claims?
Claims encompass a range of derivatives with different substituents on the core structure, offering a broad chemical scope. Still, they are specific to certain structural features.
4. What is the patent's expiration date?
Assuming standard term calculation from a 2010 priority date, the patent is expected to expire around 2030, subject to patent term extensions or adjustments.
5. How does this patent relate to others in the field?
It exists within a crowded arena of patents targeting kinase inhibitors and heterocyclic drugs, indicating high competition and the potential for license or challenge.
References
[1] USPTO Patent Database. U.S. Patent No. 8,557,852.
[2] Patent landscape reports from relevant biopharmaceutical patent offices (e.g., WIPO PATENTSCOPE).
[3] Industry patent filings related to heterocyclic kinase inhibitors.
